{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:11:20Z","timestamp":1789017080462,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and clinical outcomes of acalabrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) or refractory\/relapsed mantle cell lymphoma (MCL) in a real-world setting in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Phase IV, open-label, single-arm, multi-center, prospective study included 89 patients with CLL\/SLL (treatment naive or one or more prior therapy) and 11 patients with refractory\/relapsed MCL who received acalabrutinib capsules 100 mg orally twice daily for six 28-day cycles or until study drug discontinuation. Patients were followed up for 28 days after the drug discontinuation to collect additional safety data. The primary endpoint was the incidence of adverse events (AEs), treatment-emergent AEs (TEAEs), serious adverse events (SAEs), second primary malignancies, and other AEs of clinical interest. Secondary endpoints included objective response rate (ORR) and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By the end of the follow-up period, 48 (54%) patients in the CLL\/SLL cohort and 9 (82%) patients in the MCL cohort reported at least one AE. Of these, 38 (43%) patients in the CLL\/SLL cohort and 7 (64%) in the MCL cohort reported TEAEs, with serious TEAEs reported in 9% and 27%, respectively. Three patients in CLL\/SLL and two in MCL reported drug-related TEAEs. Drug-related deaths were reported in two MCL patients. Drug discontinuation due to AEs was reported in 3.4% and 18.2% of the CLL\/SLL and MCL cohorts, respectively. During the follow-up period, the ORR was 62% in CLL\/SLL cohort and 36% in MCL cohort, with quality of life scores maintained throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study demonstrated safety of Acalabrutinib with no new signals and encouraging clinical outcomes in Indian patients with CLL\/SLL and MCL, consistent with global clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                    <jats:p>NCT04930536.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1822178","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:33:03Z","timestamp":1789014783000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or relapsed\/refractory mantle cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Pankaj","family":"Malhotra","sequence":"first","affiliation":[{"name":"Postgraduate Institute of Medical Education and Research","place":["Chandigarh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Cancer Institute & Research Centre","place":["Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[{"name":"Tata Memorial Hospital","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Sood","sequence":"additional","affiliation":[{"name":"Medanta, The Medicity","place":["Gurugram, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Nag","sequence":"additional","affiliation":[{"name":"Tata Medical Center","place":["Kolkata, West Bengal, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Aribandi","sequence":"additional","affiliation":[{"name":"American Oncology Institute","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[{"name":"Christian Medical College","place":["Vellore, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Menon","sequence":"additional","affiliation":[{"name":"Cytecare Cancer Hospitals Pvt. Ltd","place":["Bengaluru, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Guwahati Medical College and Hospital","place":["Guwahati, Assam, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallikarjun","family":"Kalashetty","sequence":"additional","affiliation":[{"name":"Manipal Hospital","place":["Bengaluru, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Cancer Institute & Research Centre","place":["Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Sidharthan","sequence":"additional","affiliation":[{"name":"Amrita Institute of Medical Sciences","place":["Kochi, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Rajiv Gandhi Cancer Institute & Research Centre","place":["Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Shah","sequence":"additional","affiliation":[{"name":"Hemato Oncology Clinic","place":["Ahmedabad, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurav","family":"Bhave","sequence":"additional","affiliation":[{"name":"Vedant Hospital","place":["Thane\/Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Damodar","sequence":"additional","affiliation":[{"name":"Mazumdar Shaw Medical Centre, Narayana Hrudayalaya Limited","place":["Bengaluru, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-014-0488-8","article-title":"CLL: Common leukemia; uncommon presentations","volume":"32","author":"Lad","year":"2016","journal-title":"Indian J Hematol Blood Transfusion"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-012-0192-5","article-title":"Chronic lymphocytic leukemia: Inception to cure: Are we there","volume":"29","author":"Lad","year":"2013","journal-title":"Indian J Hematol Blood Transfusion"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1719099","article-title":"Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival","volume":"61","author":"Lad","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/go.20.00032","article-title":"Chronic lymphocytic leukemia: Real-world data from India","volume":"6","author":"Tejaswi","year":"2020","journal-title":"JCO Global Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1885668","article-title":"Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL","volume":"62","author":"Jindal","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802263535","article-title":"Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: Analysis after a minimum follow-up of 5 years","volume":"49","author":"Malhotra","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70403","article-title":"EHA guidelines on management of chronic lymphocytic leukemia and Richter transformation","volume":"10","author":"Eichhorst","year":"2026","journal-title":"HemaSphere"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-018-1011-4","article-title":"Reduced dose ibrutinib due to financial toxicity in CLL","volume":"35","author":"Lad","year":"2019","journal-title":"Indian J Hematol Blood Transfusion"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100201","article-title":"Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India","volume":"13","author":"Nehra","year":"2023","journal-title":"Lancet Regional Health - Southeast Asia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.6795","article-title":"Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia","volume":"27","author":"Banerji","year":"2020","journal-title":"Curr Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd014681","article-title":"Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia","volume":"2021","author":"Schmelz","year":"2021","journal-title":"Cochrane Database Systematic Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/annonc\/mdq180","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0002","article-title":"NCCN Guidelines\u00ae Insights: Chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 3.2022: Featured updates to the NCCN Guidelines","volume":"20","author":"Wierda","year":"2022","journal-title":"J Natl Compr Cancer Network"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.88475","article-title":"Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects","volume":"26","author":"Shaw","year":"2020","journal-title":"Am J Managed Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: Second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01414","article-title":"Second-generation Bruton's tyrosine kinase inhibitors: Simply the best treatments for chronic lymphocytic leukemia","volume":"39","author":"Stephens","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia","volume":"7","author":"Roeker","year":"2023","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4697842","article-title":"Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: A real-world analysis","volume":"103","author":"Nunes","year":"2024","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: A British Society for Haematology guideline","volume":"204","author":"Eyre","year":"2024","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","article-title":"Guideline for the management of mantle cell lymphoma","volume":"182","author":"McKay","year":"2018","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-00855-9","article-title":"Treatment of mantle cell lymphoma in Asia: A consensus paper from the Asian Lymphoma Study Group","volume":"13","author":"Yoon","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s155778","article-title":"Evaluating acalabrutinib in the treatment of mantle cell lymphoma: Design, development, and place in therapy","volume":"12","author":"Girard","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.46883\/2023.25921002","article-title":"Current treatments in mantle cell lymphoma","volume":"3708","author":"Avyakta Kallam Md","year":"2023","journal-title":"ONCOLOGY"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"B33","volume-title":"Abbreviated prescribing information, in acalabrutinib 100mg capsules","year":"2022"},{"key":"B34","unstructured":"Acalabrutinib\n            \n          \n          CALQUENCE (Acalabrutinib) Tablets, for Oral Use. Acalabrutinib 100mg Capsules\n          \n          2022"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1182\/blood-2019-130062","article-title":"Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: A retrospective analysis of real world patients","volume":"134","author":"Yazdy","year":"2019","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.1182\/blood-2024-194523","article-title":"Real-world effectiveness and safety outcomes of acalabrutinib treatment in patients with relapsed\/refractory mantle cell lymphoma","volume":"144","author":"Patel","year":"2024","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"1","author":"Andrew Lipsky","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B44","article-title":"A rare side effect of ibrutinib: tumor lysis syndrome","volume":"36","author":"Ozturk","year":"2021"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: A selective Bruton tyrosine kinase inhibitor for the treatment of B-cell Malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.1182\/blood-2023-191104","article-title":"Meta-analysis of the efficacy and adverse effects of acalabrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukemia","volume":"142","author":"Park","year":"2023","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood J Am Soc Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1822178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:33:10Z","timestamp":1789014790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1822178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1822178"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1822178","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1822178"}}